Reata Pharmaceuticals — Corporate Update (July 2018)
22 slides from Reata Pharmaceuticals's corporate update, Jul 23, 2018
Slide 1: Management call to discuss Phase 2 CARDINAL and PHOENIX updates
Management call to discuss phase 2 cardinal and phoenix updates Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Reata is Developing Bardoxolone in Five Rare Forms of CKD
Reata is Developing Bardoxolone in Five Rare Forms of CKD Conducting pivotal Phase 2/3 CARDINAL study in Alport syndrome (AS) Conducting Phase 2 PHOENIX study in ADPKD, IgAN, T1D CKD, and FSGS Collectively impact more than 700,000 patients in US One-third of kidney failure patients in the US have a
Slide 4: FDA Has Accepted Retained eGFR Benefit for Approval in Rare Forms of CKD
FDA Has Accepted Retained eGFR Benefit for Approval in Rare Forms of CKD The “on-treatment” eGFR improvement is the full clinical benefit to the patient, but FDA requires additional evidence that it will likely delay kidney failure Withdrawal of drug after long-term treatment provides evidence wheth
Slide 5: CARDINAL: Phase 2/3 Trial Design
CARDINAL: Phase 2/3 Trial Design CARDINAL Phase 2 is open-label and enrolled 30 patients Reported at ASN 2017 that study achieved primary endpoint of statistically significant eGFR improvement from baseline after 12 weeks of treatment Patients to be followed for two years CARDINAL pivotal Phase 3 en
Slide 6: Baseline Characteristics, Historical eGFR Decline Data and Patient Disposition
Baseline Characteristics, Historical eGFR Decline Data and Patient Disposition CARDINAL baseline characteristics representative of AS population Collected historical eGFR data for 3 years prior to study initiation 22 of 25 Phase 2 patients Average annual eGFR loss prior to study of ~4.2 ml/min Histo
Slide 7: Statistically Significant eGFR Improvement Observed in Bard Treated Patients
Statistically Significant eGFR Improvement Observed in Bard Treated Patients That Historically Declined ~4.2 ml/min Improvement after one year of treatment represents recovery of approximately two years of average loss Week 12 eGFR increase positively correlates with Week 48 eGFR increase (r=0.52; p
Slide 8: Statistically Significant Retained eGFR Benefit Observed in Bard Treated Patients
Statistically Significant Retained eGFR Benefit Observed in Bard Treated Patients Mean retained eGFR benefit at Week 52 of 4.1 ml/min (p<0.05) Bard treatment demonstrated a retained eGFR benefit after withdrawal of drug suggesting that: Bard protected kidney function during treatment Bard did not im
Slide 9: Urinary Protein Not Significantly Changed at Weeks 48 or 52
Urinary Protein Not Significantly Changed at Weeks 48 or 52 Urinary protein (UACR) not significantly different from baseline at Weeks 48 or 52 Lack of increase in urinary protein when adjusted for eGFR suggests initial increase in UACR explained by increase in GFR After initial eGFR-based increase,
Slide 10: Patient and Investigator Reported Outcomes Show Improvements
Patient and Investigator Reported Outcomes Show Improvements Patient reported outcomes are being assessed using a seven-point scale Scale includes no change and three gradations of improvement and worsening Patients and investigators assess patients’ clinical status High proportion of patients and i
Slide 11: Phase 2 Summary of Safety
Phase 2 Summary of Safety Bard well-tolerated with high retention rate through one year No discontinuations due to drug-related adverse events No drug-related SAEs, changes in blood pressure, or fluid overload-events AEs have been generally mild to moderate in intensity Most commonly reported AE is
Slide 12: CARDINAL Phase 2 Data Summary
CARDINAL Phase 2 Data Summary Observed increases in on-treatment eGFR (+10.4 ml/min) and retained eGFR (+4.1 ml/min) for one year in Bard treated patients that historically declined an average of ~4.2 ml/min annually Improvement above baseline in retained eGFR suggests disease-modifying activity Lac
Slide 13: PHOENIX Trial Design
PHOENIX Trial Design Phase 2, open-label, multi-center, US-only trial Four separate cohorts of patients with ADPKD, IgAN, T1D CKD, and FSGS Targeting enrollment of 25 to 30 patients per cohort Primary endpoint is increase in eGFR from baseline at Week 12 Enrolling large range of eGFR (30-90 ml/min)
Slide 14: Prior to Enrollment, ADPKD Patients had Progressive Loss of Kidney Function
Prior to Enrollment, ADPKD Patients had Progressive Loss of Kidney Function PHOENIX ADPKD cohort enrolled 31 patients Historical eGFR data from 3 years prior to enrollment collected for 29 of 31 patients Average annual loss of eGFR of 4.8 ml/min prior to study entry PHOENIX Initiation Characteristic
Slide 15: Statistically Significant Improved eGFR in ADPKD Patients
Statistically Significant Improved eGFR in ADPKD Patients BL eGFR Change from Baseline in eGFR (n=31) WK4 WK12 Mean ± SE 47.7 ± 2.4 6.7 ± 0.9 9.3 ± 1.4 p-value - p<0.0001 p<0.0001 Final data demonstrate statistically significant, time-dependent increase in eGFR of 9.3 ml/min Increase represents reco
Slide 16: Urinary Protein Unchanged in ADPKD Patients
Urinary Protein Unchanged in ADPKD Patients In ADPKD, the filtration barrier is not damaged and patients had normal to near-normal levels of urinary protein at baseline The filtration barrier remains relatively impermeable to blood protein Changes in GFR would not be expected to meaningfully affect
Slide 17: ADPKD Patient and Investigator Reported Outcomes Show Improvements
ADPKD Patient and Investigator Reported Outcomes Show Improvements Patient reported outcomes are being assessed in PHOENIX 23/30 (77%) patients self-assessed as improved 23/30 (77%) patients were assessed by their clinician as improved Patient Global Impression of Change (PGIC) at Week 12 Clinician
Slide 18: ADPKD Phase 2 Summary of Safety
ADPKD Phase 2 Summary of Safety Bard was well-tolerated with 28/31 (90%) completing treatment Only one patient (3%) discontinued prematurely due to a bard-related AE of fatigue No drug-related SAEs AEs were generally mild to moderate in intensity Most commonly reported AE is muscle spasms Associated
Slide 19: PHOENIX Phase 2 ADPKD Data Summary
PHOENIX Phase 2 ADPKD Data Summary Significantly improved eGFR observed in Bard treated ADPKD patients who historically declined an average of ~4.8 ml/min annually No change in urinary protein 77% of patients reported that they were clinically improved Bard well-tolerated without any drug-related SA
Slide 20: Large Body of Clinical Evidence That Bard Treatment May Delay Kidney Failure in CKD
Large Body of Clinical Evidence That Bard Treatment May Delay Kidney Failure in CKD Importantly, today’s CARDINAL data showed a positive on-treatment and retained eGFR benefit in AS patients treated with Bard for one year Provides evidence that Bard treatment may delay or prevent kidney failure Sugg
Slide 21: Bard in CKD: Recent Highlights and Key Upcoming Milestones
Bard in CKD: Recent Highlights and Key Upcoming Milestones CARDINAL trial in Alport syndrome Released one year Phase 2 data Phase 3 portion of CARDINAL underway Next milestone: One year, pivotal Phase 3 data in 2H19 PHOENIX trial in rare forms of CKD Released complete ADPKD and interim IgAN data Nex
Slide 22: s°s REATA saz
s°s REATA saz @OO barmaceuticars